| Revenue growth | Substantial H2 growth driven by premium spheres and high export volumes. |
|---|---|
| Margins | EBITDA margins improved to 17% due to shift toward premium products. |
| Demand visibility | Strong visibility with 4,000 metric tons of orders currently on hand. |
| Management confidence | Balanced but cautious regarding external regulatory timelines for plant commissioning. |
Growth
H2 growth was high-quality, fueled by premium value-added products and a 63% export revenue contribution.
Outlook
Phase 1 Unit 3 commercialization targeted by June 2026; Phase 2 follow-up by FY28.
Risks
Regulatory delays for Unit 3 Navagam and high receivables due to MNC credit terms are key risks.
Earnings Call filed with NSE, NSE: ACCENTMIC. Summary written with AI assistance from the document.
Accent Microcell Ltd: key numbers
- Share price
- ₹674.85
- Market cap
- ₹1,619 Cr
- Revenue (annual)
- ₹349.0 Cr
- Net profit (annual)
- ₹43.86 Cr
- P/E (TTM)
- 36.9×Sector 50.4×
- Promoter holding
- 53.02%-2.45% QoQ
- FII holding
- 0.91%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Accent Microcell Ltd
All →Accent Microcell Earnings Call: Key Takeaways
Accent Microcell transcript for FY26 results highlights growth driven by high-value premium products (MCC spheres, SMCC) and upcoming capacity expansion via Unit 3.
Accent Microcell Earnings Call: Key Takeaways
Accent Microcell reported FY26 revenue of ₹34,903 Lakhs (up 31.92% YoY) and PAT of ₹4,385 Lakhs (up 32.65% YoY), driven by strong export growth and expansion in pharmaceutical excipients.
Accent Microcell H2 FY26 Results: Net Profit ₹25.8 Cr, Up 55.4% YoY
Accent Microcell Ltd reported revenue from operations of ₹209.7 Cr (+51.4% YoY) and net profit of ₹25.8 Cr (+55.4% YoY) for H2 FY26.
- Key figure
- Net profit ₹25.8 Cr · +55.4% YoY